NCT03293030View on ClinicalTrials.gov

Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

PHASE4CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 22, 2018

Primary Completion Date

February 23, 2023

Study Completion Date

February 23, 2023

Conditions
Atopic DermatitisAtopic Dermatitis EczemaEczemaAtopic Dermatitis and Related Conditions
Interventions
DRUG

Dupilumab

Dupilumab treatment

Trial Locations (1)

94118

UCSF Psoriasis and Skin Treatment Center, San Francisco

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

collaborator

Sanofi

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT03293030 - Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis | Biotech Hunter | Biotech Hunter